Patients. The study population consisted of 30 patients, 16 males and 14 females, with a mean age of 4.2 years (range, 0.03 to 15.4 years). Underlying urological abnormalities (12 cases of hydronephrosis, 9 of grade III to IV vesico-ureteral reflux, 3 of uretero-pelvic junction obstruction, 2 of spastic neurogenic bladder, and 5 cases of other multiple abnormalities of the urinary tract) were present in 21 patients of whom 10 had surgical treatment for their urological abnormalities in the previous 2 weeks. One patient had renal calculosis. According to the normal values for age given by Goldsmith (7), 13 patients had renal failure, mild in 6, moderate in 5, and severe in 2 (creatinine clearance, 50 to 80, 30 to 50, and <30 ml/min per 1.73 m2, respectively). In patients <13 years old, glomerular filtration rate was estimated from plasma creatinine concentration and body length by using two different formulas for patients who were <1 year and >1 year old (24, 25) . Seven patients had been previously treated for the same infection in another hospital with appropriate doses (one case each) of co-trimoxazole, ampicillin, cefotaxime, piperacillin, gentamicin, amikacin, and netilmicin. These antibiotics were reported to be initially active in vitro against the infecting organisms. We discontinued them after at least 6 days because of microbiological failure (bacteriuria > 105 CFU/ml and the development in 6 of 7 cases of in vitro resistance to the drug as determined by Kirby-Bauer criteria). Before aztreonam treatment, seven other patients received co-trimoxazole and six received ampicillin as prophylactic antibiotics; in these cases, also, the pathogens were 310
Aztreonam is the first monobactam antibiotic to undergo clinical trials in humans. It inhibits most of the members of the family Enterobacteriaceae at concentrations of <1 ,ug/ml and also has significant activity against Pseudomonas aeruginosa but exhibits little or no activity against gram-positive bacteria and anaerobes (10, 29) . Aztreonam possesses a high degree of resistance to enzymatic hydrolysis by most of the common chromosomal and plasmid-mediated betalactamases (16) . Its limited spectrum of activity therefore gives physicians the possibility of aiming treatment at specific organisms while reducing the risk of gastrointestinal disturbances by leaving the normal anaerobic and grampositive flora undisturbed. In adults, 1 or 2 g of aztreonam given intravenously (i.v.) produces effective serum concentrations for 8 to 12 h; the drug is primarily excreted in the urine (28) . Aztreonam has been evaluated in the treatment of serious gram-negative infections in adult patients (6, 8, 20, 23) , whereas no data are available so far on its clinical efficacy and safety in pediatric patients.
We studied the bacteriological and clinical efficacy and safety of aztreonam in 30 pediatric patients with severe urinary tract infections (UTIs) caused by bacteria which were resistant to ampicillin and susceptible in vitro to the study drug. Because these infections often appear in patients with renal insufficiency, we also obtained pharmacokinetic data in 13 [26] ). Laboratory findings suggesting upper localization of the infection (erythrocyte sedimentation rate of >25 mm/1 h, C-reactive protein concentration of >20 ,ug/ml and a fever of >380C) (11) were present in 10 other patients.
In vitro susceptibility tests. Bacteria isolated from all the patients were identified by the Minitek system (BBL Microbiology Systems, Cockeysville, Md.) and were tested before therapy was started for their susceptibility to aztreonam by the disk diffusion method (Kirby-Bauer). Subsequently, the MIC of aztreonam was evaluated and compared with that of ceftizoxime, ceftriaxone, ceftazidime, gentamicin, and amikacin. MICs were determined by a microdilution method in Mueller-Hinton broth (Difco Laboratories, Detroit, Mich.) supplemented with Ca2+ (50 mg/liter) and Mg2+ (25 mg/liter) with an inoculum of 105 CFU/ml (5) .
Drug dosage and duration of therapy. A mean daily dose of 47.7 mg/kg (range, 32.4 to 63.5) of aztreonam was given intramuscularly at 12-h intervals. In four patients with moderate or severe renal failure (creatinine clearance, 21.7 to 51.7 ml/min per 1.73 M2) the interval between administrations was 18 to 24 h. The mean duration of therapy was 12 days (range, 10 to 16 days). In the patients in which serum and urine pharmacokinetics were studied, the first dose of the drug was given i.v., and blood and urine samples were collected afterwards.
Clinical and microbiological evaluation. The efficacy of the treatment was evaluated by urine cultures every 2 or 3 days until sterilization, by erythrocyte sedimentation and Creactive protein serum concentrations determined on day 4 or 5 and at the end of treatment, and by the daily temperature patterns and clinical symptoms. Follow-up urine cultures were obtained 1 to 3 days, 5 to 10 days, and 20 to 30 days after treatment was completed. Each patient was examined daily for evidence of adverse clinical effects; in addition, we performed liver function tests (serum glutamic oxalacetic transaminase, serum glutamic pyruvic transaminase, alkaline phosphatase, and total bilirubin), renal patients, P. aeruginosa isolates were susceptible to aztreonam in vitro (MIC = 2 and 8 ,ug/ml). The first, with a mixed infection, had been previously treated surgically for intrabladder ureteral stricture and vaginal atresia but still had incomplete urinary voiding. This could possibly have contributed to a slow sterilization of both P. aeruginosa and E. coli bacteriuria. The second patient was oliguric and developed P. aeruginosa UTI because of a permanent bladder catheter. He had no urological abnormality. The renal insufficiency was resolved before aztreonam treatment. A relapse occurred within 1 week in one patient with renal calculosis who was infected with a strain of P. mirabilis. Another patient had a reinfection 21 days after the end of therapy with an E. coli strain which had an in vitro susceptibility different from that of the initial infecting strain. Three patients experienced enterococcal superinfections and one patient experienced staphylococcal superinfection while being treated with aztreonam; penicillin V and dicloxacillin, respectively, were administered concurrently. Two other patients were reinfected within 1 week with strains of K. pneumoniae and P. aeruginosa that were resistant in vitro to the drug. They were successfully treated with cefotaxime and ceftazidime, respectively.
All the patients with superinfections had indwelling ureteric splints catheters or pyelostomy. Defervescence, clinical improvement, and normalization of erythrocyte sedimentation rate and of C-reactive protein serum concentrations were rapidly obtained in all patients with permanent urine sterilization. In three of six cases, superinfection was symptomatic and in five of six cases, there was a rise in erythrocyte sedimentation rate and C-reactive protein serum concentrations.
Safety (Fig. 1 ). Regression analysis of the two variables yielded the following equation: y = 0.004 x + 169.056; (y -serum concentrations in ,ug1ml; x = time in hours) with a linear correlation coefficient (r) of 0.8. Serum concentrations above the mean geometric MICs for Enterobacteriaceae isolates (0.11 ,ug/ml) were maintained up to the eighth hour in all patients, but MICs for P. aeruginosa isolates (9.2 jig/ml) were only exceeded for 2 h. Ten to twelve h after administration, mean urinary aztreonam levels (38 ,ug/ml) were 350 times higher than the mean MICs for members of Enterobacteriaceae but were only 4 times higher than mean MICs for P. aeruginosa strains (Fig. 2) .
DISCUSSION
The choice of an effective and safe antibiotic is often a major problem in patients with recurrent UTIs and severe urological abnormalities, in whom infections are mostly sustained by multiresistant bacteria (15, 31) . Aminoglycosides were used previously as first-choice antibiotics in such patients (31) . However, hospital-acquired pathogens are sometimes resistant to these antibiotics (17, 19) . Furthermore, the concomitant presence of renal failure in patients with severe urological abnormalities often makes it difficult to use this kind of drug. In the last 2 years we successfully treated such infections with new beta-lactam agents (ceftizoxime and ceftazidime) (21, 22 England, 1985) . The microbiological and clinical results obtained in this study confirm our previous in vitro data. This is particularly interesting when it is considered that 7 of the 30 patients had already been treated with other antibiotics which failed to sterilize urine and that most patients were severely ill. A relapse occurred during the follow-up period in one child with renal calculosis. However, the rate of failures and of relapses expected in this kind of patient is very high (14) . The results obtained in patients with UTIs sustained by P. aeruginosa were less satisfactory. This was possibly due to the low dosages used. In adult patients with P. aeruginosa UTIs, failures or relapses were commonly seen when aztreonam was given at a dose of 2 g or less per day (9) . Calculating the doses administered to our patients by body surface area instead of by kilogram of body weight, all children with P. aeruginosa UTI were given a dose <2 g/1.73 Mi2. The reason that higher concentrations might be needed in P. aeruginosa infections deserves consideration. Eng et al. (2) recently demonstrated a large inoculum effect and a poor bactericidal activity for aztreonam as well as for other beta-lactam antibiotics against P. aeruginosa. Since most infected urines contain bacteria at a higher density than 105 CFU/ml, it may be hypothesized that even if antibiotic concentrations in the urine are high they may in some cases be insufficient to inhibit bacterial multiplication or kill the bacteria.
Aztreonam pharmacokinetic data in pediatric patients with normal renal function were recently reported by Stutman et al. (27) . In patients 1 month to 12 years old, the serum elimination half-life was similar to that found in adult patients (1.7 h) (28) . In our children with normal renal function, the drug disappeared from the serum faster (t1/20 = 1.1 h). We have no explanation for such discrepancies, but it should be noted that t,/2 for most beta-lactams has been found to be shorter in pediatric than in adult populations (13, 22, 30) . As expected, and as previously seen in adults (3, 18) , the t1/2 value for aztreonam was increased in patients with renal impairment. In patients with moderate or severe renal failure, aztreonam concentrations in serum were still detectable 18 to 36 h after administration. Based on these data, the dose interval should be lengthened in these patients. Aztreonam was well tolerated. Hematologic and biochemical side effects in our patients were similar to those described in adult patients treated with the drug (8, 20, 23) and in pediatric patients treated with other new beta-lactam antibiotics (1, 4, 12, 21, 22) . Thus, it seems reasonably safe to use aztreonam also in severely ill patients and in patients with renal failure.
The percentage of superinfections (8, 20, 23) we found during and at the end of aztreonam treatment was also similar to that reported in comparable clinical trials in adults. Superinfections, mostly by gram-positive bacteria, were almost exclusively restricted to immunocompromised patients or to those with predisposing conditions (8, 23) .
In conclusion, these data suggest a significant clinical potential for aztreonam in the treatment of severe UTIs caused by multiresistant members of Enterobacteriaceae in pediatric populations. In patients with predisposing conditions, however, superinfections with resistant bacteria should be carefully monitored. 
